Related Experiment Video

Updated: May 30, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Recombinant canstatin inhibits angiopoietin-1-induced angiogenesis and lymphangiogenesis

Jeon Hwang-Bo1, Ki Hyun Yoo, Jong-Hwa Park

  • 1Department of Genetic Engineering and Graduate School of Biotechnology, Kyung Hee University, Yongin, Korea.

International Journal of Cancer
|August 9, 2011
PubMed

Insights

Recombinant canstatin effectively suppresses tumor growth by inhibiting angiogenesis and lymphangiogenesis. This anti-cancer agent reduces key signaling molecules like angiopoietin-1, Tie-2, and VEGFR-3, offering potential therapeutic benefits.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Angiogenesis and lymphangiogenesis are crucial for tumor growth and metastasis.
  • Canstatin, derived from Type IV collagen, is a potential anti-angiogenic agent.
  • Understanding canstatin's mechanism against tumor vascularization is vital.

Purpose of the Study:

  • To investigate the anti-angiogenic and anti-lymphangiogenic effects of recombinant canstatin.
  • To evaluate recombinant canstatin's impact on tumor growth in a preclinical model.
  • To elucidate the molecular mechanisms underlying canstatin's anti-tumoral activity.

Main Methods:

  • In vitro studies using endothelial cells (HUVEC) and lymphatic endothelial cells (LEC) treated with recombinant canstatin.
  • In vivo studies using a CT-26 colon carcinoma mouse model.
  • Analysis of gene and protein expression (angiopoietin-1, Tie-2, VEGFR-3, VEGF-C) via RT-PCR and immunohistochemistry.

Main Results:

  • Recombinant canstatin inhibited HUVEC and LEC proliferation, migration, and tube formation.
  • Tumor volume, weight, and vascular/lymphatic vessel density were reduced in canstatin-treated mice.
  • Canstatin suppressed angiopoietin-1, Tie-2, and VEGFR-3 expression in tumors and cell cultures.

Conclusions:

  • Recombinant canstatin exhibits significant anti-tumoral activity against CT-26 colon carcinoma.
  • It effectively inhibits angiogenesis and lymphangiogenesis by targeting the angiopoietin-1/Tie-2 and VEGFR-3 pathways.
  • Canstatin represents a promising therapeutic candidate for cancer treatment.

More Related Videos

Rat Mesentery Angiogenesis Assay18:30

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...